Clinical and endocrine features and long-term outcome of Graves' disease in early childhood.
Hyperthyroidism is rare in early childhood and most commonly caused by Graves' disease. We report 14 children (4 boys, 10 girls) aged 3.4-7.5 yr. At diagnosis, all patients had weight loss, hyperkinetic activity, tachycardia, difficulty sleeping, and poor concentration and 11 presented with proptosis. Four patients developed long-term neuropsychological problems. There was a family history in 7 cases. All patients had goiters, clinically assessed to be large and diffuse in 21%, medium-sized in 43%, and small in 36%. At diagnosis, height was increased with median (range) height; 1.25 standard deviation score (SDS) (-0.2-5.24) and body mass index (BMI) was decreased; -0.48 SDS (-1.65-1.26). Height and BMI SDS values were statistically different (p<0.032) Bone age was advanced in 4 of 5 children, who had assessments. Total or free T4 levels were elevated and TSH was undetectable. Ninety percent of patients (12/14) had positive thyroid peroxidase autoantibodies, mean level 680 IU/ml (range 50-1347). Initial treatment was with antithyroid medication using carbimazole; median dose 0.75 mg/kg/day (no.=13) or propylthiouracyl 15 mg/kg/day (no.=1). T4 was added in 6 patients. Normalisation of serum T4 occurred at 4 months (1- 9) and TSH at 7 months (3-24) after start of therapy. Treatment was discontinued after a minimum of 2 yr in 11 patients, relapse occurring in 9. Median duration of total therapy was 58 months (18-132). During adolescence, 4 patients had curative therapy by surgery (no.=2) or radioiodine (no.=2). In conclusion, disturbance of growth, behavioral difficulties and infrequent spontaneous remission are key features of Graves' disease in early childhood.
Bossowski
A T
AT
Department of Paediatric Endocrinology Barts and London School of Medicine and Dentistry, London, UK.
Reddy
V
V
Perry
L A
LA
Johnston
L B
LB
Banerjee
K
K
Blair
J C
JC
Savage
M O
MO
D017668:Age of Onset; D013956:Antithyroid Agents / Q000008:administration & dosage; D001289:Attention Deficit Disorder with Hyperactivity / Q000209:etiology; D002231:Carbimazole / Q000008:administration & dosage; D002648:Child; D002675:Child, Preschool; D005094:Exophthalmos / Q000209:etiology; D005260:Female; D006111:Graves Disease / Q000150:complications* / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology*; D006130:Growth Disorders / Q000209:etiology; D006801:Humans; D006948:Hyperkinesis / Q000209:etiology; D007453:Iodide Peroxidase / Q000276:immunology; D008297:Male; D011441:Propylthiouracil / Q000008:administration & dosage; D012008:Recurrence; D012189:Retrospective Studies; D012893:Sleep Wake Disorders / Q000209:etiology; D013610:Tachycardia / Q000209:etiology; D013972:Thyrotropin / Q000097:blood; D013974:Thyroxine / Q000097:blood; D015431:Weight Loss
D013956:Antithyroid Agents; D011441:Propylthiouracil; D002231:Carbimazole; D013972:Thyrotropin; D007453:Iodide Peroxidase; D013974:Thyroxine